In this episode, we sit down with Eric Verdin, CEO of the Buck Institute, one of the world’s leading institutes dedicated to aging and longevity research.
Eric has often been associated with a more rigorous and incremental approach to extending human lifespan, focused on scientific validation, measurable progress, and improving healthspan before chasing more radical ambitions. In contrast, the broader life extension movement has become known for pushing bold visions of indefinite lifespan and extreme human enhancement.
But as this conversation unfolds, it becomes clear that these approaches are far less opposed than they may seem.
We explore the relationship between moonshots and incremental progress, the role of scientific rigor in advancing longevity, and the institutional incentives that often reward performative radicalism over real-world results. The conversation also touches on regulation, public perception, and the challenge of turning longevity from a speculative idea into a field capable of delivering tangible benefits to people today.
Rather than framing ambition and rigor as competing forces, this episode examines why both are necessary to meaningfully move the field forward.
Ep. 108: The Buck Inst. President, Eric Verdin, on Pathways to Life Extension Acceleration: Alternative Pathways and Radical Hopium vs. Scientific Realism
Can longevity science balance radical ambition with scientific rigor, or does the future of life extension require both?
Stranded Technologies Podcast
Infinita is building early clinical access pathways for biotech acceleration such as Prospera and Montana SB535. This is the Infinita community's main channel for news, podcast episodes, event announcements & more.
Infinita is building early clinical access pathways for biotech acceleration such as Prospera and Montana SB535. This is the Infinita community's main channel for news, podcast episodes, event announcements & more.Listen on
Appears in episode
Recent Episodes












